Abstract. Tissue inhibitor of metalloproteinase-3 (TIMP-3) has an inhibitory effect on tumor development, growth and metastasis due to its interaction with matrix metalloproteinases (MMPs). We investigated the prognostic significance of TIMP-3 gene promoter methylation in esophageal squamous cell carcinoma (ESCC). TIMP-3 methylation was analyzed by MethyLight, a quantitative and methylation-specific PCR method. Hypermethylation was found in 9/51 (18%) surgically resected ESCC samples and was associated with reduced disease-free (p=0.0039) and overall survival (p=0.0047). Upon multivariate analysis, it was found to be an independent prognostic parameter for poor survival and was associated with earlier recurrence after surgery (p=0.0238), especially via pleural dissemination (p=0.001). Expression levels for TIMP-3 protein and for several MMPs were analyzed by Western blot analysis in 20 pairs of ESCC and adjacent normal tissue. The expression of MMP-2, -7 and -9 proteins in tumor tissue was significantly higher than in corresponding normal mucosa (p=0.0051, 0.0064 and 0.0004, respectively). In contrast, the expression of TIMP-3 protein in tumor tissue was significantly lower than in matched normal mucosa (p=0.0152). Tumors with TIMP-3 hypermethylation expressed lower levels of TIMP-3 protein compared to those without hypermethylation (p=0.0357). These results demonstrate that TIMP-3 hypermethylation is associated with lower TIMP-3 protein expression in ESCC and with poor patient survival due to a high frequency of recurrence by pleural dissemination.
Introduction
Esophageal carcinoma is one of the most common types of cancer and is associated with unfavorable patient survival due to the high proportion of patients that present with advanced stage disease. Recent progress in surgical procedure has allowed radical lymph node dissection in esophageal cancer (1) . However, postoperative local and distant recurrence is still a major problem in the management of this cancer (2, 3) . Although our general understanding of the mechanisms of cancer development and progression have improved, the molecular and biological data relating to esophageal cancer are still quite limited and poorly understood. The identification of good prognostic markers in esophageal cancer remains of major importance for improving the clinical management and outcome of patients with this disease.
Matrix metalloproteinases (MMPs) are a group of Ca 2+ -dependent, zinc-containing enzymes that degrade proteins in the extracellular matrix (4) . More than 25 MMPs have been described to date and are classified on the basis of amino acid homology, peptide structure and in vitro substrate specificity. MMPs are implicated in all aspects of tumor progression; they enhance tumor-induced angiogenesis, destroy local tissue architecture to allow tumor growth, and break down basement membranes during the process of metastatic spread. The expression of MMP-1, -2, -3, -7, -9, -11 and -13 and membrane-type MMPs (MT-MMPs) and their prognostic significance in esophageal squamous cell carcinoma (ESCC) has been reported previously (5, 6) . The activity of MMPs is regulated at the transcriptional level by cytokines and growth factors and by proenzyme activation or tissue inhibitors of MMP (TIMPs) following their secretion (7, 8) . There are four known TIMPs that complex with, and thus inactivate, both latent and active MMPs. TIMP-3 is a secreted 24-kDa glycoprotein produced by most cell types. Because of differences in function and tissue localization, the abrogation of the function ONCOLOGY REPORTS 20: 1489 -1495 , 2008 Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma . TIMP-3  is insoluble and remains bound to the extracellular matrix,  unlike other TIMP family members such as TIMP-1 and -2  which are soluble inhibitors. TIMP-3 inhibits the activity of  MMP-1, -2, -3, -9 and -13 (9) , as well as the activity of MT-MMPs (10) . It can also exert inhibitory effects on tumor progression via anti-angiogenic activity and the promotion of apoptosis (11) (12) (13) (14) . Decreased expression of TIMP-3 could therefore favor tumor growth by reducing the inhibition of MMPs and apoptotic activity and by increasing angiogenesis. The hypermethylation of gene promoters has been highlighted recently as a mechanism for gene inactivation during the development of several tumor types (15) . TIMP-3 is silenced in association with aberrant promoter hypermethylation in cell lines derived from human cancers (16) . Previous studies showed a high incidence of TIMP-3 hypermethylation in Barret's esophagus and in esophageal adenocarcinoma (17, 18) . Reduced TIMP-3 protein expression in esophageal adenocarcinoma was associated with more advanced disease and poor patient survival (18) . An immunohistochemical study showed that reduced TIMP-3 protein expression correlated with less favorable survival in ESCC patients (19) . Together, these findings suggest that TIMP-3 hypermethylation may be of clinical use as a prognostic factor due to its role in silencing gene expression. Little is known, however, regarding the silencing effect of TIMP-3 hypermethylation on gene expression and its prognostic significance in ESCC. In this study, we used a quantitative, high-throughput methylation assay, MethyLight, to investigate the frequency and clinical importance of TIMP-3 hypermethylation in 51 cases of ESCC (17, 20, 21) . Furthermore, we examined TIMP-3 gene hypermethylation in relation to the expression level of TIMP-3 protein in ESCC.
Materials and methods
Tissue samples. Fifty-one tissue specimens of primary ESCC and 38 tissue specimens from adjacent normal esophageal mucosa were obtained from patients who underwent surgery at Kanazawa University Hospital. Tissues were immediately frozen in liquid nitrogen and kept at -80˚C until use. All samples were diagnosed histopathologically as ESCC. No preoperative radiotherapy or chemotherapy had been performed for any of the cases. The clinicopathological characteristics were evaluated according to the guidelines of the Union Internationale Contre le Cancer.
DNA extraction and sodium bisulfite conversion. Genomic DNA was extracted from tissues using standard proteinase-K digestion and phenol-chloroform extraction methods (22) . Sodium bisulfite conversion of genomic DNA was performed as described previously (23) .
Methylation analysis. Following sodium bisulfite conversion of DNA, the methylation analysis was performed by a fluorescence-based, real-time PCR assay (MethyLight) as described previously (17, 20, 21, 24) . Two sets of primers and probes, designed specifically for bisulfite-converted DNA, were used: a methylated set for the TIMP-3 gene and a reference set for ß-actin to normalize for input DNA (17) . The reference primers and the probe for ß-actin gene amplification were designed for a region of the ß-actin gene that has no CpG dinucleotides, thus allowing for equal amplification regardless of methylation levels (17) . The percentage of fully methylated molecules at the TIMP-3 gene promoter was calculated by dividing the TIMP-3:ß-actin ratio of Sss-Itreated control DNA from normal esophageal mucosa and multiplying by 100. Samples containing 70% fully methylated molecules were designated as hypermethylated. The 70% cutoff value for the TIMP-3 methylation level was determined from the mean plus standard deviation of the TIMP-3 methylation level in normal mucosa which provided the best discrimination between favorable and poor survival according to tumor TIMP-3 methylation status.
Western blot analysis. The expression of TIMP-3 protein and several MMPs in 20 sets of ESCC tissue and corresponding normal esophageal mucosa was examined by Western blot analysis. Primary rabbit anti-human TIMP-3 polyclonal antibody was obtained from Chemicon (Temecula, CA). Anti-hMMP-1, -2, -7 and -9 monoclonal antibodies were obtained from Fuji Chemical Industries Ltd. (Takaoka, Japan). Cellular protein was extracted from fresh frozen tissue in lysis buffer [20 mM Tris-HCl (pH 7.4), 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate and 0.2% protease inhibitor cocktail (Sigma, St. Louis, MO)]. Solubilized protein (20 μg) in lysis buffer was denatured in loading buffer containing 40 mM DTT and electrophoresed in a 5-15% gradient SDS-polyacrylamide gel. After electrophoresis, the proteins were transferred to polyvinylidene difluoride membranes and incubated with primary antibody at a dilution of 1:2000. Horseradish peroxidase-conjugated and affinitypurified anti-rabbit immunoglobulin for TIMP-3 and anti-mouse immunoglobulin for MMPs (1:5000 dilution; Chemicon) were used as the secondary antibodies. The membrane was developed using a chemiluminescence system (ECL detection reagents; Amersham, Aylesbury, UK). To evaluate the relative amounts of protein in each lane, ß-actin served as an internal control and was measured with anti-ß-actin monoclonal antibody (Sigma; 1:5000 dilution). The immunoreactivity of each lane was measured by densitometry using image analysis software (NIH Image version 1.61). The ratio of protein level in tumor tissue to that in corresponding normal esophageal mucosa was calculated from the signal intensities. The relative magnitude of the signal for expression of each protein was standardized to that of ß-actin as the internal control.
Statistical analysis. TIMP-3 methylation status was assessed for associations with clinicopathological features using the Mann-Whitney U test for depth of invasion and histological grade and the χ 2 two-tailed test for the remaining parameters. MMP and TIMP-3 protein expression levels were compared between normal mucosa and carcinoma tissue using the Wilcoxon signed-rank test. The relative intensity of TIMP-3 protein expression in carcinoma tissue compared to corresponding normal esophageal mucosa and according to TIMP-3 methylation status was analyzed by the MannWhitney U test. Overall and disease-free survivals were calculated using the Kaplan-Meier method and compared by the Log-rank test. The prognostic significance of various parameters tested in multivariate analysis was determined by forward Cox regression analysis. Statistical analyses were performed using SPSS II for Windows (SPSS Japan, Tokyo Japan). A p-value <0.05 was considered significant.
Results

TIMP-3 hypermethylation.
Hypermethylation of the promoter region of TIMP-3 was analyzed by quantitative methylationspecific PCR (MethyLight). The average and standard deviation of TIMP-3 methylation levels in normal mucosa and carcinoma tissue were 35.5±35.9 and 72.7±226%, respectively. When TIMP-3 methylation was classified according to a 70% cutoff value, hypermethylation was found in 6/36 (17%) normal mucosal samples and 9/51 (18%) carcinoma tissue samples from ESCC patients. None of the 9 cases showing TIMP-3 hypermethylation in carcinoma tissue showed TIMP-3 hypermethylation in the corresponding normal esophageal mucosa.
The relationships between TIMP-3 hypermethylation in tumor tissue and clinicopathological parameters are listed in Table I . No significant correlations were observed between TIMP-3 hypermethylation and clinicopathological parameters in ESCC. However, patients with TIMP-3 hypermethylation had significantly poorer prognosis compared to those without. This was observed for both disease-free (p=0.0039) and overall survival (p=0.0047) (Fig. 1A and B) . Upon univariate analysis, the significant prognostic variables for predicting disease-free and overall survival were TIMP-3 hypermethylation and distant metastasis. When TIMP-3 hypermethylation and four clinicopathological parameters which are widely considered as prognostic indicators (depth of invasion, lymph node metastasis, distant metastasis, histological grade) were evaluated using multivariate analysis, TIMP-3 hypermethylation emerged as an independent prognostic factor for both disease-free and overall survival (Tables II and III) . Patients with TIMP-3 hypermethylation showed twice the rate of recurrence compared to those without (89 vs. 43%, p=0.0238) ( Table IV) . As shown in Table IV , tumors with TIMP-3 hypermethylation showed a strong predilection (5/9, 55%) for pleural dissemination (p=0.001).
Western blot analysis.
Representative results of the Western blot analysis for MMP and TIMP-3 protein expression are shown in Fig. 2 . Anti-MMP-1, -2, -7 and -9 antibodies recognized latent and active forms of each molecule with the following sizes: 52 (latent form) and 42 kDa (active form), 72 (latent form) and 62 kDa (active form), 28, 92 (latent form) and 66 kDa (active form), respectively. Immunoreactive bands in the lower molecular-weight region are presumably the result of degradation products. Anti-TIMP-3 polyclonal antibody recognized a band of 52 kDa which corresponds to the dimerized form of TIMP-3 protein. Table I . Association of TIMP-3 hypermethylation with clinicopathological parameters. Densitometric analysis for 20 matched tumor and normal tissue samples showed that expression levels for MMP-2, -7 and -9 protein were significantly higher in tumor tissue compared to corresponding normal mucosa (p=0.0051, 0.0064 and 0.0004, respectively) ( Fig. 3A-C) . The expression level for MMP-1 protein in tumor tissue did not differ with that in the corresponding normal mucosa. In contrast to the MMPs, the expression level for TIMP-3 protein in tumor tissue was significantly lower than in corresponding normal mucosa (p=0.0152) (Fig. 3D) . Hypermethylation of TIMP-3 was present in the tumor DNA of 7 of the 20 cases investigated for protein expression. These showed significantly lower levels of TIMP-3 expression in tumor tissue compared to cases without TIMP-3 hypermethylation (p=0.0357) (Fig. 4) .
-------------------------------------------------
Discussion
All ESCC patients in this study underwent curative resection with lymph node dissection at the time of surgery. The small subgroup of cases with TIMP-3 hypermethylation (18%) showed a significantly higher rate of recurrence and reduced survival after surgery compared to cases without hypermethylation of this gene. Furthermore, TIMP-3 hypermethylation emerged as an independent prognostic factor for both disease-free and overall survival in multivariate analysis that included the conventional prognostic variables. In preliminary studies we investigated the frequency and clinical relevance for the hypermethylation of 15 genes thought to be important in cancer development and progression. These were Table II . COX regression analysis for disease-free survival.
- Variable  HR  95% CI  p  HR  95% CI  p  - 
----------------------------------------------------------------------------------------------------Univariate analysis Multivariate analysis -------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
, G3-4 -----------------------------------------------------------------------------------------------------
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HR, hazard ratio; CI, confidence interval; n/a, not applicable. We found that TIMP-3 protein expression in primary ESCC tissue was reduced in association with hypermethylation of TIMP-3 (Fig. 4) . Previously, Bachman et al (16) 
normal tissue samples. These researchers concluded that methylation-associated silencing of TIMP-3 is tumor specific. Based on the non-quantitative methylation-specific PCR method, Darnton et al (18) reported the absence of TIMP-3 methylation in normal esophageal mucosa. Eads et al (24) developed a real-time, quantitative TaqMan assay with methylation-specific PCR and named this high-throughput, fluorescence-based assay MethyLight. Using this assay, they examined methylation patterns during the progression of esophageal adenocarcinoma (17) . They reported that 19% of normal esophageal mucosal samples showed TIMP-3 hypermethylation. However, TIMP-3 methylation was observed to be more frequent in intestinal metaplasia, dysplasia and adenocarcinoma compared to normal esophageal mucosa. We also examined TIMP-3 methylation in normal esophageal tissue by MethyLight and found that 17% of our samples were positive. Since MethyLight is a quantitative and highly sensitive method, it is important to determine the best cutoff level allowing good distinction between hypermethylation and hypomethylation. Eads et al (17) reported that a 4% cutoff value for fully methylated molecules gave the best discrimination between normal and premalignant/ malignant tissues. In the present study, our aim was to investigate the prognostic significance of TIMP-3 methylation in ESCC. Consequently, the 70% cutoff value used here corresponds to the mean plus standard deviation of TIMP-3 methylation in normal mucosa which resulted in the best discrimination between favorable and poor survival according to tumor TIMP-3 methylation status. It is important to note that significantly reduced TIMP-3 protein expression was noted in cases showing >70% of TIMP-3 molecules methylated (Fig. 4) .
In addition to TIMP-3 hypermethylation and the reduction of TIMP-3 protein, elevated expression of its MMP target proteins was observed in ESCC tissue relative to corresponding normal mucosa. The expression level of MMPs did not have any relation to the TIMP-3 methylation status. Expression of MMPs and TIMPs has been shown not only in malignant cells but also in stromal fibroblast-like cells and macrophages located within tumors (25) . Immunohistochemical staining has shown that TIMP-3 protein is expressed in normal squamous epithelium and in macrophages or leukocytes in the underlying lamina propria (18, 19) . TIMP-3 protein expression in tumor tissue is heterogeneous, with reduced expression at the invasive front of ESCC. Western blot assay is therefore suitable for the semi-quantitative analysis of MMP and TIMP expression in tumor tissues with mixed stromal and neoplastic components. Our analysis with non-microdissected whole tissue showed increased expression of MMPs and decreased expression of TIMP-3 in ESCC compared to normal tissue (Fig. 3) . These alterations in MMP and TIMP-3 expression may cause an imbalance in proteolytic activity. Increased proteolytic activity would be expected to facilitate primary tumor growth, angiogenesis, invasion and metastasis.
A previous immunohistochemical study showed that reduced expression of TIMP-3 protein correlated with depth of invasion, number of lymph node metastases, infiltrative growth pattern and disease stage of ESCC (19) . In the present study, TIMP-3 methylation status did not correlate with any of the clinicopathological parameters examined. However, an increased rate of recurrence via pleural cavity dissemination was noted in cases with TIMP-3 hypermethylation. When these tumors express little or no TIMP-3, increased activity of MMPs may follow, resulting in a more aggressive phenotype for invasion and metastasis and subsequent poor patient outcome (26) . High levels of MMP expression in tumor tissue was a consistent finding in the present study (Fig. 3A-C) . Cancer cells with TIMP-3 hypermethylation might therefore have an increased capacity to destroy the basement membrane of pleura and thus allow pleural dissemination.
In conclusion, TIMP-3 methylation might be a clinically useful biomarker for predicting patient survival following surgery for ESCC. It could provide stronger prognostic information than conventional clinicopathological parameters, particularly after curative resection for advanced stage disease. Furthermore, TIMP-3 hypermethylation might be a good epigenetic target for cancer treatment. The post-surgical application of a histone deacetylase inhibitor targeting the hypermethylated TIMP-3 promoter region might reduce the incidence of recurrence by pleural dissemination. Determination of the TIMP-3 methylation status can therefore provide a useful prognostic tool in ESCC and can also indicate the need for further treatment modalities following surgery.
